Skip to main content
Figure 1 | Journal of Translational Medicine

Figure 1

From: Phase 1 studies of the safety and immunogenicity of electroporated HER2/CEA DNA vaccine followed by adenoviral boost immunization in patients with solid tumors

Figure 1

V930 DNA plasmids (a) and V932 adenoviral vector (b) encoding for HER2/neu and CEA. V930 is a bivalent DNA plasmid vaccine consisting of a plasmid expressing the ECD and TM domains of HER2 and a plasmid expressing CEA fused to the B subunit of E coli LTB. V932 Ad encodes human CEA fused to LTB and the truncated version of human HER2 tumor antigen (HER2-ECDTM). The CEA-LTB expression is driven by the human CMV IE promoter, whereas mouse CMV IE promoter drives the expression of HER2-ECDTM.

Back to article page